Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
12
×
Tags
boston blog main
boston top stories
fda
life sciences
national blog main
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
12
×
san francisco blog main
12
×
san francisco top stories
clinical trials
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
national
cancer
drugs
eli lilly
alnylam pharmaceuticals
amgen
deals
gene therapy
novartis
pfizer
rna interference
sarepta therapeutics
What
fda
12
×
drug
bio
roundup
approved
drugs
medicine
new
won
approval
news
patients
time
alnylam
cancer
class
companies
decades
developed
friday
gets
medicines
migraine
oral
therapy
activity
afternoon
agency
ago
ahead
aimmune
allergy
alnylam’s
amgen
approvals
approve
aren’t
arguments
asco
august
Language
unset
Current search:
photo
×
fda
×
" san diego top stories "
×
" san francisco blog main "
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines